Diroximel fumarate (Vumerity®). HTA ID: 21047

Assessment Status Rapid Review Complete
HTA ID 21047
Drug Diroximel fumarate
Brand Vumerity®
Indication For the treatment of adult patients with relapsing-remitting multiple sclerosis
Assessment Process
Rapid review commissioned 28/10/2021
Rapid review completed 16/12/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that diroximel fumarate not be considered for reimbursement at the submitted price*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations July 2022.